Med Discovery SA

Med Discovery SA is a Swiss biopharmaceutical company established in 2002. The company is committed to the discovery and development of highly specific treatments for uro-genital cancers. Their strategy revolves around the development of protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways. Med Discovery leverages a unique in-house expertise in kallikreins, the largest class of human proteases, combined with an international network in clinical urology. Their proprietary technology platform to produce protease inhibitors allows Med Discovery to target cancers or other diseases where specific treatments are lacking. The company aims to become a leading research and development biotech company in the uro-genital field, developing products both in-house and with appropriate partners. This positioning makes Med Discovery an intriguing prospect for potential investors in the biopharmaceutical space, especially given the company's innovative approach and its potential to address unmet medical needs in uro-genital cancers.